TrialThe journal of prevention of Alzheimer's disease2022

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

C M Wischik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.